2021 Global Generic Drug Top15 is released, and the list is only half a year old, and it is a "new pharmaceutical company"!

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'> According to data released by the International Government Benchmarking Association (IGBA) in November 2020, the top 5 countries with a penetration rate of generic drugs are: India 97%, the United States 92%, Jordan 85%, Australia 84%, and Japan 77%.
Due to their high cost performance, the penetration rate of generic drugs in the world is also increasing.
Generic drugs need superb pharmaceutical technology and unremitting improvement to ensure the quality.
At the same time, they need to cooperate with superb sales skills to sell well.

According to data released by the International Government Benchmarking Association (IGBA) in November 2020, the top 5 countries with a penetration rate of generic drugs are: India 97%, the United States 92%, Jordan 85%, Australia 84%, and Japan 77%.
Due to their high cost performance, the penetration rate of generic drugs in the world is also increasing.
Generic drugs need superb pharmaceutical technology and unremitting improvement to ensure the quality.
At the same time, they need to cooperate with superb sales skills to sell well.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>According to the latest report of IMARC Group, the global generic drug market will reach US$386 billion in 2020.
By 2026, the market value is expected to reach US$517 billion, with a compound annual growth rate of 4.
9% during the forecast period (2021-2026).
.
According to our statistics, the global sales of top 15 generic drugs in 2020 will reach about 72.
7 billion US dollars.
According to the latest report of IMARC Group, the global generic drug market will reach US$386 billion in 2020.
By 2026, the market value is expected to reach US$517 billion, with a compound annual growth rate of 4.
9% during the forecast period (2021-2026).
.
According to our statistics, the global sales of top 15 generic drugs in 2020 will reach about 72.
7 billion US dollars.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Source: Company's financial report
Note: (Because Viatris has just been reorganized, revenue is based on the 21-year full-year guidelines)Source: Company's financial report
Note: (Because Viatris has just been reorganized, revenue is based on the 21-year full-year guidelines)
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>In the TOP15, there are 7 Indian pharmaceutical companies, accounting for nearly 50%, and they are veritable imitation giants with a penetration rate of 97%, ranking first in the world.
We select 6 distinctive company reviews.
In the TOP15, there are 7 Indian pharmaceutical companies, accounting for nearly 50%, and they are veritable imitation giants with a penetration rate of 97%, ranking first in the world.
We select 6 distinctive company reviews.

544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Image source: Made by Yaorong CircleImage source: Made by Yaorong Circle544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Viatris (NASDAQ: VTRS) is a new type of healthcare company formed in November 2020 through the combination of Mylan and Pfizer’s Upjohn business.
It brings together scientific, manufacturing and distribution expertise, with proven regulatory, medical And commercial capabilities to provide high-quality drugs to patients in more than 165 countries and regions.
Viatris’ portfolio includes more than 1,400 approved molecules across a wide range of therapeutic areas such as non-communicable diseases and infectious diseases, including globally recognized brands, complex generics and brand-name drugs, an increasing number of biosimilars and various An over-the-counter consumer product.
Viatris has approximately 45,000 employees worldwide and is headquartered in the United States.
Viatris has given 21-year full-year performance guidance.
Viatris Corporation Viatris Corporation Viatris Corporation(NASDAQ: VTRS) is a new type of healthcare company formed in November 2020 through the combination of Mylan and Pfizer’s Upjohn business.
It brings together scientific, manufacturing and distribution expertise and has proven With its regulatory, medical and commercial capabilities, it provides high-quality drugs to patients in more than 165 countries and regions.
Viatris’ portfolio includes more than 1,400 approved molecules across a wide range of therapeutic areas such as non-communicable diseases and infectious diseases, including globally recognized brands, complex generics and brand-name drugs, an increasing number of biosimilars and various An over-the-counter consumer product.
Viatris has approximately 45,000 employees worldwide and is headquartered in the United States.
Viatris has given 21-year full-year performance guidance.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Teva , established in 1901, currently has about 3,500 products and is one of the largest pharmaceutical companies in the world.
Nearly 200 million people from 60 countries/regions use Teva a drug every day.
In the United States, 1 out of every 9 prescriptions is filled with Teva products.
In the United Kingdom, this ratio is one-sixth; in Canada, it is one-sixth.
In addition, many prescription drugs produced by other companies contain active pharmaceutical ingredients produced by Teva.
Teva has a strong supply chain, a network of 43,000 employees and 70 global production bases working around the clock to ensure that the drug can cover patients in more than 60 countries on six continents.
In the API field, Teva api is an independent business unit of Teva Pharmaceutical Industries, providing high-quality APIs to more than 1,000 customers worldwide.
Teva api's product portfolio consists of more than 400 high-quality APIs produced in 16 state-of-the-art production plants, employing more than 5,000 well-trained professionals. Teva Teva , established in 1901, currently has about 3,500 products and is one of the largest pharmaceutical companies in the world.
Nearly 200 million people from 60 countries/regions use Teva a drug every day.
In the United States, 1 out of every 9 prescriptions is filled with Teva products.
In the United Kingdom, this ratio is one-sixth; in Canada, it is one-sixth.
In addition, many prescription drugs produced by other companies contain active pharmaceutical ingredients produced by Teva.
Teva has a strong supply chain, a network of 43,000 employees and 70 global production bases working around the clock to ensure that the drug can cover patients in more than 60 countries on six continents.
In the API field, Teva api is an independent business unit of Teva Pharmaceutical Industries, providing high-quality APIs to more than 1,000 customers worldwide.
Teva api's product portfolio consists of more than 400 high-quality APIs produced in 16 state-of-the-art production plants, employing more than 5,000 well-trained professionals. 544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Picture: tewa's rich product pipelinePicture: tewa's rich product pipeline544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>  544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Source: tewa annual reportSource: tewa annual report544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Sandoz was founded in 1886 and was also a division of Novartis Group in 1996.
In 2020, net sales were US$9.
6 billion, accounting for 20% of the group's total net sales.
Sandoz is one of the global giants of generic drugs and biosimilars.
The global product portfolio includes approximately 1,000 molecules, covering all major therapeutic areas, with products covering more than 500 million patients, in biosimilars (the "forefront" of innovative generic drugs) and generic antibiotics (the foundation of the global healthcare system) ) Occupies an important position in the world.
The main products retail generic drugs, anti-infectives and biological products. Sandoz Sandoz was founded in 1886 and was also a division of Novartis Group in 1996.
In 2020, net sales were US$9.
6 billion, accounting for 20% of the group's total net sales.
Sandoz is one of the global giants of generic drugs and biosimilars.
The global product portfolio includes approximately 1,000 molecules, covering all major therapeutic areas, with products covering more than 500 million patients, in biosimilars (the "forefront" of innovative generic drugs) and generic antibiotics (the foundation of the global healthcare system) ) Occupies an important position in the world.
The main products retail generic drugs, anti-infectives and biological products. 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>Data source: Novartis financial reportData source: Novartis financial report544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>  544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>King of Africa- Aspen has a long history of 160 years.
It is a global professional brand multinational pharmaceutical company with business in emerging and developed markets, with approximately 9,800 in 71 branches in more than 50 countries/regions.
With more than 150 employees, the products are sold in more than 150 countries/regions, and the production capacity covers a variety of product types, including sterile agents, oral solids, liquids, semi-solids, biological agents and active pharmaceutical ingredients.
It operates 23 manufacturing plants in 15 locations and has obtained international manufacturing approvals from some of the most stringent global regulatory agencies, including the U.
S.
Food and Drug Administration, the Australian Therapeutic Products Authority and the European Agency for the Quality of Medicines.
Those who are interested can look at weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247533496&idx=1&sn=9709ddda991e3e7bb07c08dbaf4a485a&chksm=fa1a2332cd6daa249b907ac5da85a6458a18a79471340f1a0bf8e99d1e41e89c0f063d54c696&scene=21#wechat_redirect" textvalue="—Aspen" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Aspen, the king of Africa, the global dominance generic drug company .
King of Africa- Aspen Aspen Aspen has a long history of 160 years.
It is a global professional brand multinational pharmaceutical company with operations in emerging and developed markets, with 71 branches in more than 50 countries/regions With approximately 9,800 employees, products are exported to more than 150 countries/regions, and its production capacity covers a variety of product types, including sterile agents, oral solids, liquids, semi-solids, biological agents and active pharmaceutical ingredients.
It operates 23 manufacturing plants in 15 locations and has obtained international manufacturing approvals from some of the most stringent global regulatory agencies, including the U.
S.
Food and Drug Administration, the Australian Therapeutic Products Authority and the European Agency for the Quality of Medicines.
Those who are interested can look at weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247533496&idx=1&sn=9709ddda991e3e7bb07c08dbaf4a485a&chksm=fa1a2332cd6daa249b907ac5da85a6458a18a79471340f1a0bf8e99d1e41e89c0f063d54c696&scene=21#wechat_redirect" textvalue="—Aspen" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Aspen, the king of Africa, the global dominance generic drug company .
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Desert Fox- Hikma was established in 1978.
After nearly 40 years of development, it currently has 31 pharmaceutical manufacturing plants/facilities and 7 R&D centers in more than 50 countries around the world, with nearly 10,000 employees and nearly 700 products.
Varieties, drug treatment categories developed include anti-infection, cardiovascular, central nervous system, diabetes, tumor, pain management and respiratory diseases, etc.
Those who are interested can see weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541772&idx=1&sn=eb2f00e3e349e420011b8e67416a4209&chksm=fa1a4486cd6dcd9080c470c43799efd2a35b21b0d93b4c107036022ce8eaf05ad0ce930ffec1&scene=21#wechat_redirect" textvalue="——" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Desert Fox, a global generic drug giant born in Jordan .
Desert Fox- Hikma Hikma was established in 1978.
After nearly 40 years of development, it currently has 31 pharmaceutical manufacturing plants/facilities and 7 R&D centers in more than 50 countries around the world, employs nearly 10,000 people, and involves nearly 700 products.
A variety of drug treatment categories, including anti-infection, cardiovascular, central nervous system, diabetes, tumor, pain management and respiratory diseases, etc.
Those who are interested can see weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541772&idx=1&sn=eb2f00e3e349e420011b8e67416a4209&chksm=fa1a4486cd6dcd9080c470c43799efd2a35b21b0d93b4c107036022ce8eaf05ad0ce930ffec1&scene=21#wechat_redirect" textvalue="——" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Desert Fox, a global generic drug giant born in Jordan .
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Japan Medical Engineering (Nichi-lko), Sawai Pharmaceutical (Sawai) and East and Yakuhin (Towa) is currently Japan's three major generic drug manufacturer.
Nichi-lko's annual revenue for 2020 is 190 billion yen, which is slightly less than that of Sawai.
Sawai Pharmaceutical was established in 1929, with revenue of 200 billion yen in 2020, ranking first in generic drugs in Japan and top 14 in the world.
Japan Biomedical Engineering Day Medical Engineering (Nichi-lko), Sawai Pharmaceutical (Sawai) and East and Yakuhin (Towa) is currently Japan's three major generic drug manufacturer.
Nichi-lko's annual revenue for 2020 is 190 billion yen, which is slightly less than that of Sawai.
Sawai Pharmaceutical was established in 1929, with revenue of 200 billion yen in 2020, ranking first in generic drugs in Japan and top 14 in the world.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>to sum upSummary Summary544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>From the list, we can see that small small countries like Israel and Jordan can breed top 10 generic drug companies in the world.
Even Africa has pharmaceutical companies on the list, but in the global top 15 generic drugs, no Chinese pharmaceutical companies are on the list.
The list is indeed worthy of our deep consideration.
On the road of generic drugs and internationalization, we still have a long way to go.
From the list, we can see that small small countries like Israel and Jordan can breed top 10 generic drug companies in the world.
Even Africa has pharmaceutical companies on the list, but in the global top 15 generic drugs, no Chinese pharmaceutical companies are on the list.
The list is indeed worthy of our deep consideration.
On the road of generic drugs and internationalization, we still have a long way to go.